Enliven Therapeutics (ELVN) Current Assets (2019 - 2026)
Enliven Therapeutics (ELVN) posted Current Assets of $463.1 million for Q1 2026, down 2.47% sequentially from $474.9 million in Q4 2025, and up 57.36% YoY from $294.3 million in Q1 2025.
Enliven Therapeutics (ELVN) Current Assets (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Current Assets for 8 years, with the latest figure at $463.1 million in Q1 2026.
- Quarterly Current Assets rose 57.36% year-over-year to $463.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $463.1 million (up 57.36% YoY) and the FY2025 annual result came in at $474.9 million, up 49.27% from the prior year.
- Current Assets retreated to $463.1 million in Q1 2026 per ELVN's latest filing, from $474.9 million in the prior quarter.
- Over five years, Current Assets peaked at $495.6 million in Q2 2025 and troughed at $59.1 million in Q3 2022.
- A 5-year average of $286.9 million and a median of $297.0 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2023: Current Assets sank 44.24% in 2022, then surged 354.46% in 2023.
- Over 5 years, Current Assets stood at $77.8 million in 2022, then surged by 242.3% to $266.2 million in 2023, then grew by 19.53% to $318.1 million in 2024, then jumped by 49.27% to $474.9 million in 2025, then declined by 2.47% to $463.1 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $463.1 million, $474.9 million, and $482.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | 907.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 907.34 Mn |
| Mar 31, 2026 | 463.14 Mn |
| Dec 31, 2025 | 474.88 Mn |
| Sep 30, 2025 | 482.68 Mn |
| Jun 30, 2025 | 495.62 Mn |
| Mar 31, 2025 | 294.32 Mn |
| Dec 31, 2024 | 318.13 Mn |
| Sep 30, 2024 | 297.00 Mn |
| Jun 30, 2024 | 318.13 Mn |
| Mar 31, 2024 | 337.20 Mn |
| Dec 31, 2023 | 266.15 Mn |
| Sep 30, 2023 | 268.61 Mn |
| Jun 30, 2023 | 283.18 Mn |
| Mar 31, 2023 | 298.00 Mn |
| Dec 31, 2022 | 77.75 Mn |
| Sep 30, 2022 | 59.10 Mn |
| Jun 30, 2022 | 64.26 Mn |
| Mar 31, 2022 | 78.53 Mn |
| Dec 31, 2021 | 92.70 Mn |
| Sep 30, 2021 | 106.00 Mn |